
Verastem's new campaign aims to make distinctions in rare type of ovarian cancer
When Tiffany Stout was first diagnosed with ovarian cancer in 2015, she didn’t immediately take in the fact that it was specifically the low-grade serous type. It wasn’t until she met with her doctor later and understood she had low-grade serous ovarian cancer (LGSOC), a rare disease that grows more slowly than the more common high-grade serous type, but that is also resistant to chemotherapy and highly recurrent.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.